NASDAQ · LEGN

Legend Biotech Corporation American

$19.27 -$2.95 (-13.28%) 1D Pre-market

Key Metrics

$4.30B
Market cap
P/E · TTM
Revenue · TTM
−$296.80M
Net income
EPS · TTM $-1.53
Dividend yield
Free cash flow
Beta · 1Y 0.47
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Jun 2 high, the share price fell 47%.

    Peak close $36.28 on Jun 2; trough close $19.27 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -47%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 2
    The stock moved +42.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 2
  • Apr 20
    The stock moved +18.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 20

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.30B
Enterprise value
Shares outstanding193.4M
52-wk range$16.24 – $42.26
Avg volume · 20D1.1M
Net cash
Book value / share
ExchangeNASDAQ
About Legend Biotech Corporation American
IPO dateJun 5, 2020
Employees2900

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings